Please check your internet connection and try again.
# Lorazepam (Benzodiazepine)
## Overview
Lorazepam is a short-acting benzodiazepine with anxiolytic, sedative, hypnotic, and anticonvulsant properties. It acts by potentiating the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor.
## Primary Indications
* Anxiety disorders
* Insomnia (short-term treatment)
* Status epilepticus (acute treatment)
* Premedication for medical procedures
## Adult Dosing
* **Anxiety:** 0.5-2 mg PO/IM/IV every 6-8 hours. Maximum daily dose generally 10 mg.
* **Insomnia:** 2-4 mg PO at bedtime.
* **Status Epilepticus:** 4 mg IV/IM initially. May repeat 4 mg every 5-10 minutes if seizures persist. Maximum dose 8 mg in a 12-hour period.
* **Premedication:** 2-4 mg PO/IM/IV 1-2 hours before procedure.
## Pediatric Dosing
* **Anxiety:** Dosing varies significantly by indication and age. Generally, 0.02-0.05 mg/kg/dose PO/IM/IV every 6-8 hours. **Consult specialized pediatric resources for precise dosing.**
* **Status Epilepticus:** 0.1 mg/kg/dose IV/IM, maximum 4 mg/dose. Repeat in 5-10 minutes if needed.
## Dose Adjustments
* **Hepatic Impairment:** Caution is advised; a dose reduction may be necessary.
* **Renal Impairment:** No specific dose adjustment is typically required, but monitor for increased CNS effects.
* **Elderly:** Start with lower doses (e.g., 0.5 mg PO BID) and titrate slowly due to increased sensitivity and risk of adverse effects.
## Contraindications
* Known hypersensitivity to lorazepam or other benzodiazepines.
* Acute narrow-angle glaucoma.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Sleep apnea.
## Adverse Effects
* **Common:** Sedation, drowsiness, dizziness, weakness, ataxia.
* **Serious:** Respiratory depression (especially when combined with other CNS depressants), paradoxical reactions (agitation, aggression), anterograde amnesia, dependence, withdrawal symptoms.
## Key Drug Interactions
* **CNS Depressants (opioids, alcohol, other sedatives, antihistamines):** Increased risk of profound sedation, respiratory depression, coma, and death. Use with extreme caution or avoid.
* **CYP450 Inhibitors/Inducers:** Lorazepam is metabolized via glucuronidation, not primarily by CYP enzymes, thus interactions are less common but can occur.
## Monitoring
* Level of consciousness and sedation.
* Respiratory rate and depth.
* Mental status (especially for paradoxical reactions).
* Signs of dependence or withdrawal if used long-term.
## Clinical Pearls
* Intramuscular (IM) absorption can be slow and erratic; intravenous (IV) administration is preferred for rapid effect.
* Intravenous lorazepam injection should be given slowly to minimize risk of respiratory depression.
* Avoid abrupt discontinuation after prolonged use to prevent withdrawal symptoms. Tapering is recommended.
* Consider use for the shortest effective duration due to potential for tolerance, dependence, and withdrawal.
***
*Please verify current prescribing information and local protocols for definitive guidance.*
